http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 31 Oct 2025 06:07:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NovaBridge+Biosciences++++For%3A+Oct+31/25533354.html si-local-file:///var/storage/secattach/20251031/25533354.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NovaBridge+Biosciences++++For%3A+Oct+31/25533354.html Fri, 31 Oct 2025 06:07:00 -0500 IMAB NBP O.38348529 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NovaBridge+Biosciences++++For%3A+Oct+31/25533354.html si-local-file:///var/storage/secattach/20251031/25533354.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NovaBridge+Biosciences++++For%3A+Oct+31/25533354.html Fri, 31 Oct 2025 06:07:00 -0500 IMAB NBP O.38348529 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NovaBridge+Biosciences++++For%3A+Oct+31/25533354.html si-local-file:///var/storage/secattach/20251031/25533354.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NovaBridge+Biosciences++++For%3A+Oct+31/25533354.html Fri, 31 Oct 2025 06:07:00 -0500 IMAB NBP O.38348529 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NovaBridge+Biosciences++++For%3A+Oct+29/25524123.html si-local-file:///var/storage/secattach/20251030/25524123.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NovaBridge+Biosciences++++For%3A+Oct+29/25524123.html Thu, 30 Oct 2025 06:04:00 -0500 IMAB O.38348529 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NovaBridge+Biosciences++++For%3A+Oct+29/25524123.html si-local-file:///var/storage/secattach/20251030/25524123.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NovaBridge+Biosciences++++For%3A+Oct+29/25524123.html Thu, 30 Oct 2025 06:04:00 -0500 IMAB O.38348529 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++NovaBridge+Biosciences+++++++++++++++/25523876.html si-local-file:///var/storage/secattach/20251030/25523876.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++NovaBridge+Biosciences+++++++++++++++/25523876.html Thu, 30 Oct 2025 06:00:00 -0500 IMAB O.38348529 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++NovaBridge+Biosciences+++++++++++++++/25523876.html si-local-file:///var/storage/secattach/20251030/25523876.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++NovaBridge+Biosciences+++++++++++++++/25523876.html Thu, 30 Oct 2025 06:00:00 -0500 IMAB O.38348529 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NovaBridge+Biosciences++++For%3A+Oct+29/25521296.html si-local-file:///var/storage/secattach/20251029/25521296.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NovaBridge+Biosciences++++For%3A+Oct+29/25521296.html Wed, 29 Oct 2025 16:05:00 -0500 IMAB O.38348529 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NovaBridge+Biosciences++++For%3A+Oct+29/25521296.html si-local-file:///var/storage/secattach/20251029/25521296.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NovaBridge+Biosciences++++For%3A+Oct+29/25521296.html Wed, 29 Oct 2025 16:05:00 -0500 IMAB O.38348529 http://www.streetinsider.com/Corporate+News/I-MAB+rebrands+as+NovaBridge+Biosciences%2C+ticker+changes+to+NBP/25518054.html <p>I-MAB (NASDAQ: IMAB) announced it has changed its corporate name to NovaBridge Biosciences, with trading under the new ticker symbol "NBP" beginning October 30, 2025. The name change was approved by shareholders at an extraordinary general meeting on October 24, 2025.</p><p>The rebrand accompanies the company's strategic transformation into a global biotechnology platform. NovaBridge plans to pursue a dual listing on both NASDAQ and the Hong Kong Stock Exchange through a planned Hong Kong initial public offering, though timing and terms remain undetermined.</p><p>Under its new hub-and-spoke business model, NovaBridge formed subsidiary Visara, Inc., which acquired VIS-101, a bifunctional biologic targeting VEGF-A http://www.streetinsider.com/Corporate+News/I-MAB+rebrands+as+NovaBridge+Biosciences%2C+ticker+changes+to+NBP/25518054.html Wed, 29 Oct 2025 09:01:49 -0500 IMAB NBP http://www.streetinsider.com/Corporate+News/I-MAB+rebrands+as+NovaBridge+Biosciences%2C+ticker+changes+to+NBP/25518054.html <p>I-MAB (NASDAQ: IMAB) announced it has changed its corporate name to NovaBridge Biosciences, with trading under the new ticker symbol "NBP" beginning October 30, 2025. The name change was approved by shareholders at an extraordinary general meeting on October 24, 2025.</p><p>The rebrand accompanies the company's strategic transformation into a global biotechnology platform. NovaBridge plans to pursue a dual listing on both NASDAQ and the Hong Kong Stock Exchange through a planned Hong Kong initial public offering, though timing and terms remain undetermined.</p><p>Under its new hub-and-spoke business model, NovaBridge formed subsidiary Visara, Inc., which acquired VIS-101, a bifunctional biologic targeting VEGF-A http://www.streetinsider.com/Corporate+News/I-MAB+rebrands+as+NovaBridge+Biosciences%2C+ticker+changes+to+NBP/25518054.html Wed, 29 Oct 2025 09:01:49 -0500 IMAB NBP http://www.streetinsider.com/Press+Releases/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html <ul type="disc"><li>New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide</li><li>Strategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX)</li><li>Consistent with the new hub-and-spoke business model, the Company has formed a new subsidiary, Visara, Inc. (Visara), which acquired VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2 that could potentially provide more effective and durable treatment than the current standard of care for patients with wet AMD and DME</li><li>Company core asset, givastomig, http://www.streetinsider.com/Press+Releases/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html Wed, 29 Oct 2025 09:00:00 -0500 A.09642568 A.27185794 A.39990104 IMAB NBP O.02674903 O.20371933 O.38348529 O.41905748 http://www.streetinsider.com/Press+Releases/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html <ul type="disc"><li>New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide</li><li>Strategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX)</li><li>Consistent with the new hub-and-spoke business model, the Company has formed a new subsidiary, Visara, Inc. (Visara), which acquired VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2 that could potentially provide more effective and durable treatment than the current standard of care for patients with wet AMD and DME</li><li>Company core asset, givastomig, http://www.streetinsider.com/Press+Releases/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html Wed, 29 Oct 2025 09:00:00 -0500 A.09642568 A.27185794 A.39990104 IMAB NBP O.02674903 O.20371933 O.38348529 O.41905748 http://www.streetinsider.com/Press+Releases/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html <ul type="disc"><li>New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide</li><li>Strategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX)</li><li>Consistent with the new hub-and-spoke business model, the Company has formed a new subsidiary, Visara, Inc. (Visara), which acquired VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2 that could potentially provide more effective and durable treatment than the current standard of care for patients with wet AMD and DME</li><li>Company core asset, givastomig, http://www.streetinsider.com/Press+Releases/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html Wed, 29 Oct 2025 09:00:00 -0500 A.09642568 A.27185794 A.39990104 IMAB NBP O.02674903 O.20371933 O.38348529 O.41905748 http://www.streetinsider.com/Press+Releases/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html <ul type="disc"><li>New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide</li><li>Strategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX)</li><li>Consistent with the new hub-and-spoke business model, the Company has formed a new subsidiary, Visara, Inc. (Visara), which acquired VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2 that could potentially provide more effective and durable treatment than the current standard of care for patients with wet AMD and DME</li><li>Company core asset, givastomig, http://www.streetinsider.com/Press+Releases/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html Wed, 29 Oct 2025 09:00:00 -0500 A.09642568 A.27185794 A.39990104 IMAB NBP O.02674903 O.20371933 O.38348529 O.41905748 http://www.streetinsider.com/Press+Releases/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html <ul type="disc"><li>New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide</li><li>Strategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX)</li><li>Consistent with the new hub-and-spoke business model, the Company has formed a new subsidiary, Visara, Inc. (Visara), which acquired VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2 that could potentially provide more effective and durable treatment than the current standard of care for patients with wet AMD and DME</li><li>Company core asset, givastomig, http://www.streetinsider.com/Press+Releases/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html Wed, 29 Oct 2025 09:00:00 -0500 A.09642568 A.27185794 A.39990104 IMAB NBP O.02674903 O.20371933 O.38348529 O.41905748 http://www.streetinsider.com/Press+Releases/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html <ul type="disc"><li>New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide</li><li>Strategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX)</li><li>Consistent with the new hub-and-spoke business model, the Company has formed a new subsidiary, Visara, Inc. (Visara), which acquired VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2 that could potentially provide more effective and durable treatment than the current standard of care for patients with wet AMD and DME</li><li>Company core asset, givastomig, http://www.streetinsider.com/Press+Releases/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html Wed, 29 Oct 2025 09:00:00 -0500 A.09642568 A.27185794 A.39990104 IMAB NBP O.02674903 O.20371933 O.38348529 O.41905748 http://www.streetinsider.com/Press+Releases/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html <ul type="disc"><li>New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide</li><li>Strategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX)</li><li>Consistent with the new hub-and-spoke business model, the Company has formed a new subsidiary, Visara, Inc. (Visara), which acquired VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2 that could potentially provide more effective and durable treatment than the current standard of care for patients with wet AMD and DME</li><li>Company core asset, givastomig, http://www.streetinsider.com/Press+Releases/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html Wed, 29 Oct 2025 09:00:00 -0500 A.09642568 A.27185794 A.39990104 IMAB NBP O.02674903 O.20371933 O.38348529 O.41905748 http://www.streetinsider.com/Press+Releases/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html <ul type="disc"><li>New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide</li><li>Strategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX)</li><li>Consistent with the new hub-and-spoke business model, the Company has formed a new subsidiary, Visara, Inc. (Visara), which acquired VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2 that could potentially provide more effective and durable treatment than the current standard of care for patients with wet AMD and DME</li><li>Company core asset, givastomig, http://www.streetinsider.com/Press+Releases/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html Wed, 29 Oct 2025 09:00:00 -0500 A.09642568 A.27185794 A.39990104 IMAB NBP O.02674903 O.20371933 O.38348529 O.41905748 http://www.streetinsider.com/Press+Releases/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html <ul type="disc"><li>New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide</li><li>Strategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX)</li><li>Consistent with the new hub-and-spoke business model, the Company has formed a new subsidiary, Visara, Inc. (Visara), which acquired VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2 that could potentially provide more effective and durable treatment than the current standard of care for patients with wet AMD and DME</li><li>Company core asset, givastomig, http://www.streetinsider.com/Press+Releases/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html Wed, 29 Oct 2025 09:00:00 -0500 A.09642568 A.27185794 A.39990104 IMAB NBP O.02674903 O.20371933 O.38348529 O.41905748 http://www.streetinsider.com/Globe+Newswire/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html <ul type="disc"><li>New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide</li><li>Strategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX)</li><li>Consistent with the new hub-and-spoke business model, the Company has formed a new subsidiary, Visara, Inc. (Visara), which acquired VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2 that could potentially provide more effective and durable treatment than the current standard of care for patients with wet AMD and DME</li><li>Company core asset, givastomig, http://www.streetinsider.com/Globe+Newswire/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html Wed, 29 Oct 2025 09:00:00 -0500 A.09642568 A.27185794 A.39990104 IMAB NBP O.02674903 O.20371933 O.38348529 O.41905748 http://www.streetinsider.com/Globe+Newswire/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html <ul type="disc"><li>New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide</li><li>Strategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX)</li><li>Consistent with the new hub-and-spoke business model, the Company has formed a new subsidiary, Visara, Inc. (Visara), which acquired VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2 that could potentially provide more effective and durable treatment than the current standard of care for patients with wet AMD and DME</li><li>Company core asset, givastomig, http://www.streetinsider.com/Globe+Newswire/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html Wed, 29 Oct 2025 09:00:00 -0500 A.09642568 A.27185794 A.39990104 IMAB NBP O.02674903 O.20371933 O.38348529 O.41905748 http://www.streetinsider.com/Globe+Newswire/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html <ul type="disc"><li>New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide</li><li>Strategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX)</li><li>Consistent with the new hub-and-spoke business model, the Company has formed a new subsidiary, Visara, Inc. (Visara), which acquired VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2 that could potentially provide more effective and durable treatment than the current standard of care for patients with wet AMD and DME</li><li>Company core asset, givastomig, http://www.streetinsider.com/Globe+Newswire/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html Wed, 29 Oct 2025 09:00:00 -0500 A.09642568 A.27185794 A.39990104 IMAB NBP O.02674903 O.20371933 O.38348529 O.41905748 http://www.streetinsider.com/Globe+Newswire/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html <ul type="disc"><li>New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide</li><li>Strategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX)</li><li>Consistent with the new hub-and-spoke business model, the Company has formed a new subsidiary, Visara, Inc. (Visara), which acquired VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2 that could potentially provide more effective and durable treatment than the current standard of care for patients with wet AMD and DME</li><li>Company core asset, givastomig, http://www.streetinsider.com/Globe+Newswire/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html Wed, 29 Oct 2025 09:00:00 -0500 A.09642568 A.27185794 A.39990104 IMAB NBP O.02674903 O.20371933 O.38348529 O.41905748 http://www.streetinsider.com/Globe+Newswire/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html <ul type="disc"><li>New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide</li><li>Strategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX)</li><li>Consistent with the new hub-and-spoke business model, the Company has formed a new subsidiary, Visara, Inc. (Visara), which acquired VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2 that could potentially provide more effective and durable treatment than the current standard of care for patients with wet AMD and DME</li><li>Company core asset, givastomig, http://www.streetinsider.com/Globe+Newswire/I-MAB+%28Nasdaq%3A+IMAB%29+Transitions+to+NovaBridge+Biosciences+%28Nasdaq%3A+NBP%29+with+Trading+Effective+October+30%2C+2025+New+Brand+and+Logo+to+Reflect+Strategic+Transformation+to+a+Global+Biotech+Platform/25517954.html Wed, 29 Oct 2025 09:00:00 -0500 A.09642568 A.27185794 A.39990104 IMAB NBP O.02674903 O.20371933 O.38348529 O.41905748